 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...5354555657585960616263...235236» |
- | Biomarker, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. (Pubmed Central) - Apr 17, 2023
P2
Cobimetinib plus atezolizumab had an unfavourable benefit:risk ratio in HER2?/MSS/BRAF mCRC. New strategies are required to increase the susceptibility of MSS mCRC to immunotherapy.
- | Journal, Metastases: Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer. (Pubmed Central) - Apr 17, 2023
P2
Lesions from responders in the LOS+FFX+CRT-treated group had reduced Tregs, decreased C-FOXP3 and increased CD8+ T cells. These findings suggest that losartan may potentiate the benefit of FFX+CRT by reducing immunosuppression.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab-containing regimens. (Pubmed Central) - Apr 14, 2023
These findings suggest that losartan may potentiate the benefit of FFX+CRT by reducing immunosuppression. PTR improved the OS in patients with RAS wild-type synchronous left-sided colon or rectum cancer treated with cetuximab-containing chemotherapy regimens.
- | Journal, Metastases: Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter? (Pubmed Central) - Apr 14, 2023
In the present study the ECOG performance status showed a stronger prognostic value than patient age in FLOT as first- line therapy in a real-life cohort with advanced and metastatic GC and AEG. The performance status should therefore be considered in the therapeutic decision making of elderly patients with GC and AEG.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX. (Pubmed Central) - Apr 14, 2023
Continued adjuvant mFOLFIRINOX and post-treatment CA 19-9 level were associated with survival in patients with BRPC or LAPC who received neoadjuvant FOLFIRINOX and surgery. Continued adjuvant mFOLFIRINOX after neoadjuvant FOLFIRINOX could be considered for patients with good performance.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
“There are no treatments left that would give me a meaningful extension of my life.” Extraordinarily sad to read. But a better end than my friend who had FOLFOX to virtually his dying day, for mCRC, all sickness, no benefit. More importantly, no fair discussion of any of it. (Twitter) - Apr 13, 2023
- || Lonsurf (trifluridine/tipiracil) / Otsuka, Opdivo (nivolumab) / BMS
Trial initiation date: LOGICAN: Oxaliplatin (clinicaltrials.gov) - Apr 13, 2023
P2, N=118, Recruiting, Sponsor: UNICANCER
Continued adjuvant mFOLFIRINOX after neoadjuvant FOLFIRINOX could be considered for patients with good performance. Initiation date: Mar 2023 --> Dec 2023
- ||| Trial completion, Metastases: AFEMA: Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (clinicaltrials.gov) - Apr 13, 2023
P2, N=170, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Initiation date: Mar 2023 --> Dec 2023 Active, not recruiting --> Completed
- | Trial completion: CALGB-80803: PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Apr 13, 2023
P2, N=257, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Clinical, HEOR: “At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group” 12 years and zero progress‽ (Twitter) - Apr 12, 2023
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date, Metastases: NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 12, 2023
P2, N=200, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Jun 2023
- | TTX-030 / AbbVie, Trishula Therap
Trial completion date, Metastases: ELTIVATE: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov) - Apr 12, 2023
P1, N=185, Active, not recruiting, Sponsor: Trishula Therapeutics, Inc.
Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Jun 2023 Trial completion date: Dec 2022 --> Jun 2024
- || Trial completion date, Trial primary completion date, Metastases: AFEMA: Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (clinicaltrials.gov) - Apr 12, 2023
P2, N=170, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial completion date: Dec 2022 --> Jun 2024 Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Dec 2022 --> May 2023
- | oxaliplatin / Generic mfg.
Enrollment open: The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy (clinicaltrials.gov) - Apr 12, 2023
P3, N=64, Recruiting, Sponsor: Tanta University
Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Dec 2022 --> May 2023 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer (clinicaltrials.gov) - Apr 12, 2023
P2, N=77, Active, not recruiting, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Oct 2021 --> Dec 2023
- ||| pimurutamab (HLX07) / Fosun Pharma
Trial completion, Enrollment change, Metastases: HLX07Ib/II: The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (clinicaltrials.gov) - Apr 12, 2023
P1/2, N=56, Completed, Sponsor: Shanghai Henlius Biotech
Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Oct 2021 --> Dec 2023 Active, not recruiting --> Completed | N=90 --> 56
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Metastases: Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis @AnnSurgOncol @McMastersKelly @IHPBA @SocSurgOnc @SSATNews https://t.co/ykqtLrOhFy (Twitter) - Apr 11, 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal: Preoperative liver arterial conditioning in patients scheduled for a Mayo Clinic class Ia distal pancreatectomy: embolization or ligation? (Pubmed Central) - Apr 11, 2023
Preoperative AE and LL seem comparable in averting arterial reconstruction and postoperative liver insufficiency in patients scheduled for class Ia DP-CAR. However, serious complications that may arise during AE led us to prefer the LL technique.
- | Retrospective data, Journal, HEOR, Metastases: Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival. (Pubmed Central) - Apr 11, 2023
In this real-world population-based study of patients with uLAPC, FOLFIRINOX was associated with improved survival and higher resection rates. FOLFIRINOX was associated with improved survival in patients with uLAPC after accounting for the effect of post-chemotherapy surgical resection, suggesting the benefit of FOLFIRINOX was not solely due to improving resectability.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal: Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan. (Pubmed Central) - Apr 11, 2023
FOLFIRINOX was associated with improved survival in patients with uLAPC after accounting for the effect of post-chemotherapy surgical resection, suggesting the benefit of FOLFIRINOX was not solely due to improving resectability. S-1 monotherapy and FOLFOX are comparable as the subsequent chemotherapy after gemcitabine-based chemotherapy-induced ILD in unresectable PDAC.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Retrospective data, Journal, Metastases: Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer. (Pubmed Central) - Apr 11, 2023
S-1 monotherapy and FOLFOX are comparable as the subsequent chemotherapy after gemcitabine-based chemotherapy-induced ILD in unresectable PDAC. SCRT followed by oxaliplatin-based consolidation chemotherapy is safe and effective for tumor downstaging in LARC, further improving the sphincter preservation rate.
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Trial completion date: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 11, 2023
P3, N=847, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
SCRT followed by oxaliplatin-based consolidation chemotherapy is safe and effective for tumor downstaging in LARC, further improving the sphincter preservation rate. Trial completion date: Dec 2027 --> Sep 2023
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Apr 11, 2023
P2, N=92, Active, not recruiting, Sponsor: National Health Research Institutes, Taiwan
Trial completion date: Dec 2027 --> Sep 2023 Unknown status --> Active, not recruiting | N=46 --> 92 | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Trial primary completion date: T2317: Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy (clinicaltrials.gov) - Apr 11, 2023
P2, N=59, Completed, Sponsor: National Health Research Institutes, Taiwan
Unknown status --> Active, not recruiting | N=46 --> 92 | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023 Active, not recruiting --> Completed | Trial primary completion date: Dec 2021 --> Dec 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Metastases: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Apr 11, 2023
P2, N=28, Completed, Sponsor: Brown University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2021 --> Dec 2022 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
Enrollment open, Trial initiation date: NCI-2022-09458: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 10, 2023
P1/2, N=86, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF mutation status. (Pubmed Central) - Apr 9, 2023
Maintenance therapy with FP plus biologic agents (either bevacizumab or cetuximab) is a feasible strategy for appropriate mCRC patients according to their RAS/BRAF status. Further large-scale randomized studies are needed to validate the efficacy of anti-epidermal growth factor receptor-based maintenance therapy.
- ||| GEJunction Adenocarcinoma:(fluorouracil [5-FU], leucovorin, oxaliplatin, and docetaxel [FLOT] chemotherapy versus FLOT plus trastuzumab and pertuzumab -no advantage of later (Twitter) - Apr 7, 2023
- ||||||||| Cosela (trilaciclib) / G1 Therap
Trial completion date, Trial termination, Metastases: PRESERVE 1: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (clinicaltrials.gov) - Apr 7, 2023
P3, N=326, Terminated, Sponsor: G1 Therapeutics, Inc.
Trial completion date: Jul 2025 --> Mar 2023 | Active, not recruiting --> Terminated; Despite achieving co-primary endpoints & other secondary measures of myeloprotection & tolerability, early anti-tumor efficacy data favor patients receiving placebo. Given the low likelihood of achieving PFS & OS endpoints, G1 decided to discontinue
- | Avastin (bevacizumab) / Roche
Biomarker, Enrollment change, Combination therapy, Metastases: AC-ANGIOPREDICT: ANGIOPREDICT. ICORG 12-16, V3 (clinicaltrials.gov) - Apr 6, 2023
P2, N=76, Completed, Sponsor: Cancer Trials Ireland
Given the low likelihood of achieving PFS & OS endpoints, G1 decided to discontinue N=224 --> 76
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Opdivo (nivolumab) / BMS
New P1 trial: Aldesleukin with Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer with Peritoneal Metastasis (clinicaltrials.gov) - Apr 6, 2023
P1b, N=15, Not yet recruiting, Sponsor: Mayo Clinic
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Vectibix (panitumumab) / Amgen, Takeda
Biomarker, Clinical, Metastases: Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212) https://t.co/rAp0ySURP9 (Twitter) - Apr 5, 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal: Pancreatectomy After Neoadjuvant FOLFIRINOX Chemotherapy: Identifying Factors Predicting Long-Term Survival. (Pubmed Central) - Apr 5, 2023
A multimodal treatment, including neoadjuvant FOLFIRINOX combined with pancreatectomy with venous and arterial resection, achieves long term survival rates in patients with locally advanced disease. Surgery, in experienced centers, should be integrated into the treatment of patients with locally advanced pancreatic adenocarcinomas.
- |||||| Erbitux (cetuximab) / Eli Lilly, cetuximab biosimilar / CinnaGen
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Apr 5, 2023
P3, N=234, Recruiting, Sponsor: Cinnagen
Surgery, in experienced centers, should be integrated into the treatment of patients with locally advanced pancreatic adenocarcinomas. Unknown status --> Recruiting | Trial completion date: Feb 2020 --> Feb 2026 | Trial primary completion date: Nov 2019 --> Nov 2025
- || 5-fluorouracil / Generic mfg.
Review, Journal: Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review. (Pubmed Central) - Apr 4, 2023
It is important to note that while 5-FU-induced hyperammonemic encephalopathy is rare, it highlights the importance of closely monitoring patients receiving chemotherapy to identify and treat adverse events promptly. This can help improve patient outcomes and prevent serious long-term complications.
- ||||| Clinical, Metastases: Introducing: Phase I/II clinical trial of Botensilimab Balstilimab Bevacizumab FOLFOX (3-B FOLFOX) in the management of metastatic MSS colorectal cancer. Single Center Trial at City of Hope. NOW ENROLLING. https://t.co/U0qGCcgM56 (Twitter) - Apr 4, 2023
- | methotrexate IV / Generic mfg., methotrexate / Generic mfg.
Journal: Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study. (Pubmed Central) - Apr 4, 2023
This can help improve patient outcomes and prevent serious long-term complications. Reduction of pre-hydration duration does not affect HD-MTX induced nephrotoxicity and MTX36 levels in children <?12
- | leucovorin calcium / Generic mfg.
Clinical Trial,Phase II, Journal: A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged???80 (Pubmed Central) - Apr 4, 2023
Reduction of pre-hydration duration does not affect HD-MTX induced nephrotoxicity and MTX36 levels in children <?12 The indications for adjuvant UFT/LV therapy for elderly CRC aged???80
- | 5-fluorouracil / Generic mfg.
Biomarker, Journal: Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Apr 4, 2023
SMAD4 alterations were associated with more frequent development of metastasis and lower probability of reaching surgical resection during neoadjuvant FOLFIRINOX but not gemcitabine/nab-paclitaxel. Confirmation in a larger, diverse patient cohort will be important before prospective evaluation of SMAD4 as a genomic biomarker to guide treatment selection.
- | Herceptin (trastuzumab) / Roche, emavusertib (CA-4948) / Curis, Dr. Reddy's
Trial completion date, Trial primary completion date: CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (clinicaltrials.gov) - Apr 4, 2023
P1, N=42, Not yet recruiting, Sponsor: Washington University School of Medicine
Confirmation in a larger, diverse patient cohort will be important before prospective evaluation of SMAD4 as a genomic biomarker to guide treatment selection. Trial completion date: Apr 2027 --> Jul 2027 | Trial primary completion date: Jun 2026 --> Sep 2026
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Organ Preservation in Early Rectal Cancer Patients (clinicaltrials.gov) - Apr 4, 2023
P2, N=19, Recruiting, Sponsor: Fox Chase Cancer Center
Trial completion date: Apr 2027 --> Jul 2027 | Trial primary completion date: Jun 2026 --> Sep 2026 Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2023 --> Mar 2024
- || Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Apr 4, 2023
P2, N=75, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2023 --> Mar 2024 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- | New P3 trial, Circulating tumor DNA: Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA (clinicaltrials.gov) - Apr 4, 2023
P3, N=346, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P3 trial: Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients (clinicaltrials.gov) - Apr 4, 2023
P3, N=366, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu (clinicaltrials.gov) - Apr 4, 2023
P2, N=30, Recruiting, Sponsor: China Medical University, China
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Combination therapy: NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 4, 2023
P2, N=45, Active, not recruiting, Sponsor: University of Florida
Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- | leucovorin calcium / Generic mfg.
New P3 trial: PSYCARE: Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis (clinicaltrials.gov) - Apr 3, 2023
P3, N=500, Not yet recruiting, Sponsor: Centre Hospitalier St Anne
- || leucovorin calcium / Generic mfg.
@DrLizConnolly great trial! What’s the mtx dose and when do you start folinic acid rescue in this setting? (Twitter) - Mar 31, 2023